Carbamazepine intravenous - Lundbeck

Drug Profile

Carbamazepine intravenous - Lundbeck

Alternative Names: Carbamazepine IV; Carbella; Carnexiv

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator OVATION Pharmaceuticals
  • Developer Lundbeck Inc
  • Class Antidepressants; Antiepileptic drugs; Antimanics; Dibenzazepines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epilepsy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Epilepsy

Most Recent Events

  • 07 Oct 2016 Registered for Epilepsy in USA (IV)
  • 22 Apr 2016 US FDA accepts resubmission of NDA for carbamazepine intravenous for Epilepsy for review
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top